Helmerich & Payne director granted 5,273 shares

Helmerich & Payne, Inc. director Belgacem Chariag reported an equity award of common stock.

Rhea-AI Filing Summary

Helmerich & Payne, Inc. director Belgacem Chariag reported an equity award of common stock. On March 5, 2026, he acquired 5,273 shares of common stock as a grant/award acquisition at a stated price of $0.00 per share.

After this award, his directly owned holdings increased to 67,056 common shares. The transaction is classified as a non-derivative acquisition rather than an open‑market purchase or sale.

Insider Trade Summary

Grant/Award: 5,273 shares

Grant/Award 1 txn

Insider Chariag Belgacem

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,273	$0.00	$0.00

Holdings After Transaction: Common Stock — 67,056 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Helmerich & Payne (HP) director Belgacem Chariag report in this Form 4?

Belgacem Chariag reported receiving an award of 5,273 shares of Helmerich & Payne common stock. The filing classifies it as a grant or other acquisition, increasing his directly held non-derivative share ownership in the company.

How many Helmerich & Payne (HP) shares did Belgacem Chariag acquire?

Belgacem Chariag acquired 5,273 shares of Helmerich & Payne common stock. These shares were reported as a non-derivative grant or award transaction, with a stated transaction price of $0.00 per share in the Form 4 filing.

What is Belgacem Chariag’s total Helmerich & Payne (HP) ownership after this transaction?

Following the reported award, Belgacem Chariag directly owns 67,056 shares of Helmerich & Payne common stock. This total reflects his holdings after adding the 5,273-share non-derivative grant reported in the Form 4.

Was the Helmerich & Payne (HP) Form 4 transaction an open-market buy or sell?

The Form 4 does not show an open-market buy or sell. Instead, it records a non-derivative grant or award acquisition of 5,273 common shares at a stated price of $0.00 per share to director Belgacem Chariag.

When did the Helmerich & Payne (HP) share grant to Belgacem Chariag occur?

The share grant to Belgacem Chariag occurred on March 5, 2026. On that date, he was awarded 5,273 shares of Helmerich & Payne common stock as a non-derivative grant or other acquisition under the company’s compensation arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:06 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chariag Belgacem

(Last) (First) (Middle)

222 N. DETROIT AVE.

(Street)

TULSA OK 74120

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Helmerich & Payne, Inc. [ HP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		5,273	A	$0	67,056	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ William H. Gault by Power of Attorney for Belgacem Chariag	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.